DK0386997T3 - Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler - Google Patents

Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler

Info

Publication number
DK0386997T3
DK0386997T3 DK90302365.3T DK90302365T DK0386997T3 DK 0386997 T3 DK0386997 T3 DK 0386997T3 DK 90302365 T DK90302365 T DK 90302365T DK 0386997 T3 DK0386997 T3 DK 0386997T3
Authority
DK
Denmark
Prior art keywords
tetrahydro
inflammation
phenyl
treatment
psychosis
Prior art date
Application number
DK90302365.3T
Other languages
English (en)
Inventor
Kenneth B Koe
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0386997(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0386997T3 publication Critical patent/DK0386997T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK90302365.3T 1989-03-07 1990-03-06 Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler DK0386997T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Publications (1)

Publication Number Publication Date
DK0386997T3 true DK0386997T3 (da) 1997-04-14

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90302365.3T DK0386997T3 (da) 1989-03-07 1990-03-06 Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler

Country Status (17)

Country Link
US (2) US4981870A (da)
EP (1) EP0386997B1 (da)
JP (2) JPH0714870B2 (da)
KR (1) KR920005810B1 (da)
AT (1) ATE150299T1 (da)
AU (1) AU610036B2 (da)
CA (1) CA2011428C (da)
DE (1) DE69030212T2 (da)
DK (1) DK0386997T3 (da)
HU (1) HU221624B1 (da)
IE (1) IE81047B1 (da)
IL (1) IL93576A (da)
MY (1) MY106272A (da)
NZ (1) NZ232800A (da)
PH (1) PH26542A (da)
PT (1) PT93351B (da)
ZA (1) ZA901743B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO1991009594A1 (en) * 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
WO1995000131A1 (en) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Sigma receptor ligands and the use thereof
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
AU739261B2 (en) 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
AU1724301A (en) 1999-12-23 2001-07-09 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
JP4610336B2 (ja) * 2002-09-16 2011-01-12 セプラコール インク． トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US20040087661A1 (en) * 2002-09-16 2004-05-06 Sepracor, Inc. Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CZ2006427A3 (cs) * 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
ES2566479T3 (es) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2816024B8 (en) * 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007143267A2 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8445002B2 (en) 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2015175514A1 (en) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
EP3143000A4 (en) * 2014-05-13 2017-12-13 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of adhd
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
PH26542A (en) 1992-08-19
ZA901743B (en) 1991-10-30
DE69030212D1 (de) 1997-04-24
EP0386997A2 (en) 1990-09-12
IL93576A0 (en) 1990-11-29
HU901325D0 (en) 1990-05-28
JP3020808B2 (ja) 2000-03-15
US4981870A (en) 1991-01-01
CA2011428C (en) 1994-11-08
KR920005810B1 (ko) 1992-07-20
HUT59000A (en) 1992-04-28
US5061728A (en) 1991-10-29
JPH0714870B2 (ja) 1995-02-22
JPH02300121A (ja) 1990-12-12
IL93576A (en) 1995-12-08
EP0386997A3 (en) 1992-04-29
KR900013949A (ko) 1990-10-22
ATE150299T1 (de) 1997-04-15
AU610036B2 (en) 1991-05-09
DE69030212T2 (de) 1997-06-26
IE81047B1 (en) 1999-12-01
EP0386997B1 (en) 1997-03-19
CA2011428A1 (en) 1990-09-07
NZ232800A (en) 1997-07-27
PT93351A (pt) 1990-11-07
IE900798L (en) 1990-09-07
PT93351B (pt) 1996-03-29
JPH07173056A (ja) 1995-07-11
AU5079690A (en) 1990-09-20
MY106272A (en) 1995-04-29
HU221624B1 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
DK0386997T3 (da) Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler
NO944430L (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
DE69200837D1 (en) 3-difluoromethylpyrazolcarboxamidfungizide.
DK0605293T3 (da) Polymersammensætninger med lav gulningsgrad, polymeriserbare sammensætninger og deraf fremstillede linser
IT1231107B (it) Procedimento e dispositivo per la fabbricazione di lattine mediante stiramento.
ITTO930346A0 (it) Procedimento per la preparazione di derivati taurocolanici.
DE69022957T2 (de) Spanner.
FI932454A0 (fi) Ansiktsemulsionskompositioner som laemnas pao huden
NO953989D0 (no) Nye polysykliske systemer og derivater derav, som neurotransmitter frigivelses-forsökende midler som er anvendbare ved behandling av kognitive sykdommer
ES2115055T3 (es) 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.
IT1241497B (it) Dispositivo di regolazione del gas
ITMI940802A0 (it) Procedimento per la preparazione di derivati di 5.6 diidrossi-2-ammino-1,2,3,4- tetraidronaftalene
ZA893310B (en) Novel strobilurine derivatives,their preparation and their use
ITMI931684A0 (it) Procedimento per la preparazione di derivati del 5,4- diidrocarbostirile
MX9201610A (es) Proceso para el tratamiento de una aleacion argentifera.
FR2704421B1 (fr) Prothèse ligamentaire.
IT229855Y1 (it) Le tabelle fonetiche
SE8503513L (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
FI924721A (fi) 2,3-dideoxy-4-tioribonukleosider som antivirala aemnen
ITRM910406A0 (it) Variatore di diagramma di distribuzione.
FI58U1 (fi) Borstanordning foer anslutning till en arbetsmaskins skopa
ITMI931201A1 (it) Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
SE9304237D0 (sv) Anordning som möjliggör flyttandet av möbler i vertikalled
FI83U1 (fi) Limtraebalk eller -fackverk, som monteras pao byggnadsplatsen
KR950005520U (ko) 유아용 식탁의자